This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lissett, C. A. Articles by Shalet, S. M. Search for Related Content PubMed PubMed Citation Articles by Lissett, C. A. Articles by Shalet, S. M.

The Impact of Dose and Route of Estrogen Administration on the Somatotropic Axis in Normal Women

Department of Endocrinology, Christie Hospital, Manchester, United Kingdom M20 4BX

Address all correspondence and requests for reprints to: Prof. S. M. Shalet, Department of Endocrinology, Christie Hospital, Manchester, United Kingdom M20 4BX. E-mail: stephen.m.shalet{at}man.ac.uk.

Oral estrogen therapy has reliably been found to reduce levels of serum IGF-I and increase mean 24-h GH levels in postmenopausal women as well as increase GH requirements in patients with GH deficiency. It is thought to act by inhibiting GH-stimulated IGF-I secretion, thus resulting in diminished feedback at the hypothalamic-pituitary axis and, hence, increased GH levels. In contrast, the administration of transdermal estrogen has variably been found to reduce, not change or increase, levels of serum IGF-I. We sought to clarify the effect of transdermal estrogen on the GH/IGF-I axis by using the IGF-I generation test, in which the acute response to a bolus dose of GH is examined. Nine healthy postmenopausal women received three different formulations of estrogen: oral estradiol (1 mg every 12 h), transdermal estradiol (50 µg/d), and transdermal estradiol (200 µg/d) for a 6-wk period in random order, separated by an 8-wk washout period. At the start of the study and in the last week of each estrogen formulation treatment, subjects underwent an IGF-I generation test. Oral estradiol reduced baseline (P < 0.05) and GH stimulated (P < 0.05) IGF-I levels, and GH stimulated IGF-binding protein-3 (IGFBP-3) levels (P < 0.05). High dose transdermal estrogen did not affect basal levels of IGF-I or IGFBP-3, but reduced the response of these GH-dependent peptides to GH stimulation (P < 0.05). Low dose transdermal estrogen did not alter either baseline or peak IGF-I levels, but reduced the peak IGFBP-3 response to GH stimulation (P < 0.05). Estradiol levels were lower during both transdermal estrogen preparations than during oral estrogen. It has been suggested that the effect of estrogen on responsiveness to GH is limited to that administered by the oral route. We have demonstrated that transdermal estrogen also has a significant impact on responsiveness to GH despite achieving levels of circulating estrogen lower than those achieved by oral estrogen replacement.

Abbreviations: ALS, Acid-labile subunit; GHD, GH deficiency; IGFBP-3, IGF-binding protein-3.

This article has been cited by other articles:

				P. Kok, R. C. Paulo, M. Cosma, K. L. Mielke, J. M. Miles, C. Y. Bowers, and J. D. Veldhuis Estrogen Supplementation Selectively Enhances Hypothalamo-Pituitary Sensitivity to Ghrelin in Postmenopausal Women J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 4020 - 4026. [Abstract] [Full Text] [PDF]

				A. A van der Klaauw, N. R Biermasz, P. M J Zelissen, A. M Pereira, E. G W M Lentjes, J. W A Smit, S. W van Thiel, J. A Romijn, and F. Roelfsema Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism Eur. J. Endocrinol., December 1, 2007; 157(6): 709 - 716. [Abstract] [Full Text] [PDF]

				N. Bouhours-Nouet, F. Gatelais, F. Boux de Casson, S. Rouleau, and R. Coutant The Insulin-Like Growth Factor-I Response to Growth Hormone Is Increased in Prepubertal Children with Obesity and Tall Stature J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 629 - 635. [Abstract] [Full Text] [PDF]

				H. K Gleeson and S. M Shalet GH responsiveness varies during the menstrual cycle Eur. J. Endocrinol., December 1, 2005; 153(6): 775 - 779. [Abstract] [Full Text] [PDF]

				D. Fintini, M. Alba, and R. Salvatori Influence of Estrogen Administration on the Growth Response to Growth Hormone (GH) in GH-Deficient Mice Exp Biol Med, November 1, 2005; 230(10): 715 - 720. [Abstract] [Full Text] [PDF]

				P. M. Mah, J. Webster, P. Jonsson, U. Feldt-Rasmussen, M. Koltowska-Haggstrom, and R. J. M. Ross Estrogen Replacement in Women of Fertile Years with Hypopituitarism J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 5964 - 5969. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, D. Erickson, K. Mielke, L. S. Farhy, D. M. Keenan, and C. Y. Bowers Distinctive Inhibitory Mechanisms of Age and Relative Visceral Adiposity on Growth Hormone Secretion in Pre- and Postmenopausal Women Studied under a Hypogonadal Clamp J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6006 - 6013. [Abstract] [Full Text] [PDF]

				G. G T'Sjoen, Y. Beguin, E. Feyen, R. Rubens, J.-M. Kaufman, and L. Gooren Influence of exogenous oestrogen or (anti-) androgen administration on soluble transferrin receptor in human plasma J. Endocrinol., July 1, 2005; 186(1): 61 - 67. [Abstract] [Full Text] [PDF]

				D. Erickson, D. M. Keenan, L. Farhy, K. Mielke, C. Y. Bowers, and J. D. Veldhuis Determinants of Dual Secretagogue Drive of Burst-Like Growth Hormone Secretion in Premenopausal Women Studied under a Selective Estradiol Clamp J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1741 - 1751. [Abstract] [Full Text] [PDF]

				H. K. Gleeson, C. A. Lissett, and S. M. Shalet Insulin-Like Growth Factor-I Response to a Single Bolus of Growth Hormone Is Increased in Obesity J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1061 - 1067. [Abstract] [Full Text] [PDF]

				R. Coutant, F. B. de Casson, S. Rouleau, O. Douay, E. Mathieu, F. Gatelais, N. Bouhours-Nouet, C. Voinot, M. Audran, and J. M. Limal Divergent Effect of Endogenous and Exogenous Sex Steroids on the Insulin-Like Growth Factor I Response to Growth Hormone in Short Normal Adolescents J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6185 - 6192. [Abstract] [Full Text] [PDF]